Today's Rundown AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug Pain intensifies for AbbVie as it slashes 178 jobs from Stemcentrx Gilead and Galapagos’ big drug hope hits arthritis goal in latest phase 3 tests Xcovery hires CEO, CMO to lead assault on ALK NSCLC market Proteon tanks after kidney disease drug fails again in phase 3 EuroBiotech Report—U.K. VC funding, Ono, Polyneuron round, ProQR and Inflazome FiercePharmaAsia—Eisai’s new Alzheimer’s trial; AZ supports China; Ono invests in I-O Chutes & Ladders—Allergan taps Celgene vet Bob Hugin for M&A guidance Featured Story | | | Friday, March 29, 2019 AstraZeneca is willing to bet nearly $7 billion on an antibody drug conjugate out of Japanese pharma Daiichi’s pipeline as it looks beyond checkpoint inhibitor Imfinzi. |
|
|
Top Stories Thursday, March 28, 2019 It was a $6 billion deal that was meant to help bolster AbbVie’s pipeline and help wean the biopharma off its Humira reliance, but Stemcentrx has proven to be a major thorn in its side. Now, the time has come to start digging it out. Friday, March 29, 2019 Gilead and Galapagos have notched another series of late-stage wins for their JAK inhibitor filgotinib, with one analyst saying safety “looks clean” after recent scares in the class. Friday, March 29, 2019 Xcovery has hired a CEO and CMO with Big Pharma experience to lead its efforts to challenge Pfizer, Roche and others for a lung cancer market. Li Mao, formerly of Johnson & Johnson, has taken the top job at Xcovery as the biotech heads toward phase 3 readouts on an ALK inhibitor. Friday, March 29, 2019 Proteon Therapeutics has failed another phase 3 chronic kidney disease trial. The latest failure raised significant doubts about the future of vonapanitase, wiping 85% off Proteon’s stock price and leaving the company to consider strategic alternatives. Thursday, March 28, 2019 In this week's EuroBiotech Report, U.K. venture capital funding jumps 35%, Ono joins U.K. immuno-oncology alliance and Sofinnova and NEA back a Swiss startup. Friday, March 29, 2019 Eisai started phase 3 testing of Alzheimer's candidate BAN2401, one day after the aducanumab flop; AstraZeneca invested in a new life sciences research hub in China as Japan's Ono Pharma formed an immuno-oncology pact in the U.K.; and more. Friday, March 29, 2019 Allergan taps Celgene veteran Bob Hugin for M&A guidance; Imara gains former Pfizer rare disease executive as CMO; and iTeos brings on Sanofi cancer VP as CMO. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is Covance. | | | Advancing a Diabetes Multi-Registration Program
Learn how Covance helped a sponsor who wanted to get all sites for a 2,700 patient study up and running as quickly as possible. Covance leveraged their proprietary historical investigator performance database to see which investigators outperformed their peers on a consistent basis and had the capacity to run multiple studies at the same time. Download the Case Study now. |
Resources Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Patheon, part of Thermo Fisher Scientific The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: ON24 Which HCP Touchpoints and channels are yielding the best results in today’s digital world? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Drug Development Immersion April 3-4, 2019 | Philadelphia, PA BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! Calling Europe – Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 